

Resonance Health Ltd

ACN 006 762 492

Annual General Meeting

16 November 2011



RHT – Year in Review

- Solid growth in FerriScan[®] sales volume
- Significant progress towards reimbursement for FerriScan in the U.S.
- FDA approval achieved for cardiac iron diagnostic test
- HepaFat Scan[™] shows technical superiority to competitors in fatty liver diagnosis - U.S. FDA submission being prepared
- Liver fibrosis test in development
- Strong Australian dollar has had a negative impact on income



Resonance Health Product Portfolio

Research

Proof of
concept

Validate

U.S.
510K

On
Market

Reimbur-
sement


FerriScan[®] (liver iron assessment)

(Canada/
UK)

Cardiac T2* (cardiac iron assessment)


HepaFat Scan[™] (liver fat test)

Liver Fibrosis Test





FerriScan[®] Sales Growth

FerriScan sales





* Increase in year-on-year sales





Global Access to FerriScan®





FerriScan[®] Summary

- 2010-11 FerriScan results
 - 14% growth in FerriScan sales volumes
 - U.S. FerriScan sales volumes up 35%, revenue up 19%
 - U.K. FerriScan sales volumes up 105%, revenue up 72%
 - Strong growth in new FerriScan users – in Brazil, Japan, Italy and China
 - Negative impact of strong Australian dollar (80% revenue in USD)
- Distributors engaged to target Middle East markets
- U.S. reimbursement
 - Positive responses from Medical Directors of public and private insurers
 - RHT is confident of gaining FerriScan insurance coverage in the U.S.
- Novartis Master Service Agreement
 - Two new contracts signed for FerriScan services in clinical trials
 - Broad education of Novartis customers and staff on FerriScan





U.S. Payer Targets for FerriScan[®]

Public Payers

Centers for Medicare & Medicaid
(CMS)

Medicare: 8 regions

Medicaid: 50 states

Medicaid MS
(Mississippi)

Medicaid LA
(Louisiana)

Medicaid CA Medi-Cal
(California)

Private Payers

(>4,000 plans)

Aetna
(National)


Humana
(National)

Blue Cross Blue
Shield

Cigna
(National)

Medical Mutual
(OHIO)

Kaiser
(Regional)




HepaFat Scan™

- MRI test for quantifying liver fat
- Clinical study of 59 subjects has been completed - the HepaFat Scan™ measurement of fat was compared to a liver biopsy assessment of fat
- **HepaFat Scan™ demonstrated higher levels of sensitivity and specificity than any other published method**
- Resonance Health is now seeking international patent protection
- USA FDA submission planned for Q1, 2012

HepaFat Scan™ Market

Nonalcoholic Fatty Liver Disease




- NAFLD is the most common cause of liver disease in the Western world
- Prevalence of NAFLD is 30% increasing to 90% for the morbidly obese
- NASH (nonalcoholic steatohepatitis) involves inflammatory processes
- 16% of liver transplants in the USA are due to NASH
- NAFLD is projected to be the leading cause of liver transplantation by 2020
- NAFLD can cause liver cirrhosis, a primary cause of liver cancer



HepaFat Scan™ Market

- Currently no FDA approved imaging technology for quantifying liver fat
- There are 50 million obese Americans (BMI >30)
- Approximately 30% of the US population has fatty liver disease
- Majority of patients fail to reach their goal weight with lifestyle changes alone (diet and exercise)
- Significant interest from pharmaceutical companies to develop therapies to reduce fat in the liver
- 183 trials registered on *clinicaltrials.gov* for the clinical indication of NAFLD or NASH



Liver Fibrosis Measurement

- Proof of concept study completed in 2010 showed promising results for using MRI to measure liver fibrosis
- Further development of a liver fibrosis test is in progress
 - study of 30 patients at the Austin Liver Transplant Unit in collaboration with Pfizer
 - Patient recruitment has been completed
 - Results of the study are expected in early 2012
- Excellent partnership and licensing potential
- Next Steps
 - Review results of study in early 2012
 - Explore licensing and partnership opportunities
 - Potential FDA regulatory submission in late 2012



Large Liver Fibrosis Market

- Liver fibrosis is caused by fatty liver disease, viral hepatitis, iron overload and excess alcohol consumption
- Viral hepatitis affects 170m people world wide
- If left untreated, liver fibrosis can progress to liver cirrhosis
- Liver cirrhosis is one of the top 10 causes of death in the USA and is a significant predictor of liver cancer
- Early diagnosis and effective management can significantly improve patient outcomes
- Pharmaceutical companies and clinicians need access to an accurate non-invasive diagnostic tool for assessing liver fibrosis




FY 2011: Financial Results

- Revenue down 5%
 - Negative impact of strong Australian dollar - average exchange rate during the year was 99.2 cents, 10 year average is 78.75 cents
- Expenditure increased 9%
 - R&D expenditure was \$455k (\$564k in 2009-10) to improve efficiencies in the FerriScan product and develop a pipeline for future growth in large addressable markets
 - Marketing expenditure focused on gaining FerriScan reimbursement
- Loss reported of \$317k
 - U.S. dollar income exchanged at 10 year average would have resulted in a profit
- Cash on Hand at 30 June of \$1.5m
 - R&D tax claims cleared by ATO of \$450k




Summary

- Strength of the Australian dollar has adversely affected financial results
- Solid growth in the commercial use of FerriScan and substantial progress towards gaining U.S. reimbursement
- Distributors engaged for entry into new geographic regions
- Pipeline products in large addressable markets with excellent partnering potential
- FDA application for HepaFat Scan™ on target for Q1, 2012
- Engagement with strategic partners for the development of MRI liver fibrosis test



Resonance Health Limited


Resolutions



Resolution 1

Adoption of the Remuneration Report

| | For | Against | Abstaining | Discretionary |
|-------|------------|----------------|-------------------|----------------------|
| Res 1 | 10,253,819 | 478,030 | 84,760,483 | 2,389,585 |



Resolution 2

The re-election of Simon Panton

| | For | Against | Abstaining | Discretionary |
|-------|------------|----------------|-------------------|----------------------|
| Res 2 | 95,031,684 | 450,448 | 10,200 | 2,389,585 |